Lexicon Pharmaceuticals, Inc. reported $41M of revenue over the trailing twelve months, −29% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $41M (to Q2 2026). Net income: −$61M, trailing twelve months to Q2 2026. Operating margin: −1049%, trailing twelve months to Q2 2026. EPS: −$0.15, trailing twelve months to Q2 2026.

LXRXLexicon Pharmaceuticals, Inc.

Healthcare

$1.67+40% 1Y

$1.67

$1.1452 weeks$2.50

LXRX as reported

Lexicon Pharmaceuticals, Inc. reported $41M of revenue over the trailing twelve months, −29% on the year before. 10 reported series are charted on this page, each one as filed.

$41M

Revenue, trailing twelve months · to Q2 2026 · −29% against the twelve months before

Net income: −$61M
Net income · −49% year on year · trailing twelve months to Q2 2026
Operating margin: −1049%
Operating margin · trailing twelve months to Q2 2026
EPS: −$0.15
EPS · −55% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for LXRX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$41M	−29%	Q2 2026
Net income	−$61M	−49%	Q2 2026
EPS	−$0.15	−55%	Q2 2026
Gross margin	98%	n/a	Q2 2026
Operating margin	−1049%	n/a	Q2 2026
Net margin	−1242%	n/a	Q2 2026
ROE	−38%	n/a	Q2 2026
ROA	−24%	n/a	Q2 2026
ROIC	−73%	n/a	Q2 2026
Free cash flow	−$180M	n/a	Q4 2024 · 6 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.